Mesoblast Limited has grown revenue −38% a year over three years and −15% a year over five. Revenue growth, 3-year annual rate: −38% (Biotechnology median +17%). Revenue growth, 5-year rate: −15%, growth has slowed since the five-year average. Years of annual history on file: 10, FY2016 to FY2025, as filed.

MESOMesoblast Limited

Healthcare

$14.28-16% 1Y

$14.28

$13.6252 weeks$20.96

Is it growing?

Watch

Revenue shrinking (−24% year on year). That is the only one of 3 checks this filer's data supports, so take it as a single data point rather than a settled answer.

1 to watch, 2 without data

Revenue trend−24% in a yearSEC EDGAR · Jun 30, 2023

Trailing-twelve-month revenue vs a year earlier, from the company's own filings.

Where this answer is blind. These are trailing numbers from the filings, not forecasts: an acquisition or a one-off year can flatter them, so check the quarters.

Is MESO growing?

Mesoblast Limited has grown revenue −38% a year over three years and −15% a year over five.

−38%

Revenue growth, 3-year annual rate · Biotechnology median +17% · shrinking · compounded from trailing twelve-month revenue

Revenue growth, 5-year rate: −15%
Revenue growth, 5-year rate · −38% over three · growth has slowed since the five-year average
Years of annual history on file: 10
Years of annual history on file · FY2016 to FY2025, as filed

Details›